🔍 Featured Answer: What Is Epithalon and Why Is It Central to Telomere Research?
Question: What is Epithalon and what makes it scientifically significant in anti-aging and longevity research?
Direct Answer: Epithalon (also spelled Epitalon; chemical name: Ala-Glu-Asp-Gly) is a synthetic tetrapeptide derived from the natural polypeptide Epithalamin, originally extracted from the bovine pineal gland by Professor Vladimir Khavinson at the St. Petersburg Institute of Bioregulation and Gerontology. Research demonstrates it is a potent telomerase activator — stimulating the enzyme responsible for maintaining telomere length — and modulates melatonin synthesis and several longevity-associated gene expression programs, making it one of the most studied peptides in anti-aging science.
Supporting Context: Over 40 years of research originating from the Russian Institute of Bioregulation and Gerontology under Professor Khavinson have generated an extensive body of preclinical and some human data on Epithalon’s effects on telomere length, lifespan, neuroendocrine regulation, and cancer resistance. Soviet and post-Soviet clinical research — while not meeting modern Western RCT standards — provides a broader human evidence base than most research peptides, making Epithalon uniquely positioned in the longevity research space.
- Epithalon is a synthetic tetrapeptide (Ala-Glu-Asp-Gly) derived from the pineal gland polypeptide Epithalamin, with over 40 years of research history
- Research identifies Epithalon as a telomerase activator — the first peptide shown to stimulate telomerase activity in human somatic cells in vitro
- Animal studies show Epithalon treatment extends median and maximum lifespan in rodents by 13–25% versus controls
- Human studies (Russian clinical research, 1980s–2000s) report reduced all-cause mortality and improved biomarker profiles in elderly populations treated with Epithalamin/Epithalon
- Epithalon regulates pineal gland melatonin synthesis, with downstream effects on circadian rhythm, antioxidant defence, and neuroendocrine ageing
- Expert-level understanding of Epithalon requires familiarity with telomere biology, Hayflick limit theory, and the limitations of Soviet-era clinical research methodology
- Research-grade Epithalon is available as a lyophilised peptide; long-term human pharmacokinetic data remains incomplete
Table of Contents
- What Is Epithalon? Origins and Discovery
- Telomere Biology: The Scientific Foundation
- Epithalon as a Telomerase Activator: The Core Mechanism
- Pineal Gland, Melatonin, and Neuroendocrine Regulation
- Lifespan Extension Studies: Animal Model Evidence
- Human Evidence: Russian Clinical Research
- Cancer Biology and Anti-Tumour Research
- Gene Expression and Epigenetic Research
- Epithalon vs Other Longevity Peptides: Research Comparison
- Key Research Numbers
- The Biohacker Perspective: Epithalon in Self-Experimentation Culture
- Limitations and Research Gaps
- Frequently Asked Questions
- Related Articles
- Related Products
- Related Research Plans
- Scientific References
- Conclusion
What Is Epithalon? Origins and Discovery
Epithalon’s scientific history begins in the Soviet Union in the 1970s, when Professor Vladimir Khavinson — then a young gerontologist at the Leningrad Military Medical Academy — began investigating the biological effects of pineal gland extracts on ageing and immune function. The pineal gland, a small endocrine structure in the brain responsible for melatonin synthesis, was known to regulate circadian rhythms and immune function, and its progressive atrophy with age had been correlated with accelerated biological ageing in animal models.
Khavinson’s group isolated a polypeptide extract from bovine pineal glands, termed Epithalamin, which demonstrated significant bioregulatory effects in rodent ageing studies — including lifespan extension, immune enhancement, and tumour suppression. Subsequent biochemical characterisation of the active fraction of Epithalamin led to the identification of a minimal active sequence: the tetrapeptide Ala-Glu-Asp-Gly, which Khavinson’s group named Epithalon (or Epitalon in some transliterations). This synthetic tetrapeptide retained the core biological activity of the larger natural extract while offering the advantages of chemical synthesis: defined composition, high purity, and reproducible manufacturing.
Khavinson’s Institute of Bioregulation and Gerontology in St. Petersburg became the primary centre for Epithalon research over the following four decades, generating over 100 publications examining its effects on telomere length, lifespan, neuroendocrine function, antioxidant capacity, gene expression, and oncology in both animal models and human subjects. This depth of investigation from a single research centre — mirrored in the BPC-157 literature from Zagreb — provides a rich, if methodologically variable, evidence base.
Research-grade Epithalon is synthesised via standard Fmoc solid-phase peptide synthesis and is commercially available as a lyophilised powder at high purity levels for research applications. Its small size (four amino acids, molecular weight ~390 Da) makes it structurally simple to synthesise and characterise, and its high purity can be reliably verified by HPLC and mass spectrometry.
Telomere Biology: The Scientific Foundation
To understand Epithalon’s mechanism, expert researchers must first have a firm grasp of telomere biology — the foundational science that explains why telomere length has been proposed as a biomarker and driver of biological ageing. Telomeres are repetitive DNA sequences (TTAGGG repeats in vertebrates) that cap the ends of chromosomes, protecting them from degradation, end-to-end fusion, and recognition as double-strand breaks by DNA damage response machinery.
The central problem telomeres solve is the “end-replication problem” — the inability of conventional DNA polymerase to fully replicate the lagging strand at chromosome ends, resulting in progressive loss of terminal DNA sequences with each cell division. Without a compensatory mechanism, this process predicts that somatic cells can undergo only a finite number of divisions — the Hayflick limit, approximately 50–70 divisions for human somatic cells — before critically short telomeres trigger cell senescence or apoptosis.
Telomerase is the ribonucleoprotein enzyme that counteracts this attrition by adding new TTAGGG repeats to chromosome ends using an internal RNA template (the TERC component). In embryonic stem cells, germ line cells, and some highly proliferative adult tissues, telomerase activity maintains telomere length. In most adult somatic cells, however, telomerase is expressed at low or undetectable levels, allowing telomere attrition to proceed with age — a pattern observed across virtually all human tissue types studied.
Age-associated telomere shortening correlates with multiple hallmarks of ageing: cellular senescence accumulation (the SASP — senescence-associated secretory phenotype — drives systemic inflammation), increased cancer incidence, reduced stem cell self-renewal, and organ dysfunction. This correlation has fuelled intense research into telomerase activators as potential anti-ageing interventions — the scientific context in which Epithalon’s telomerase-activating properties are evaluated.
Key Insight: Telomerase activation presents a fundamental tension in longevity research: while short telomeres are associated with ageing pathologies, uncontrolled telomerase activation is a hallmark of cancer — approximately 85–90% of human cancers are telomerase-positive, using telomere maintenance to achieve replicative immortality. This paradox means that telomerase activators must be studied carefully for both pro-longevity and potential pro-oncogenic effects across the full spectrum of doses and treatment durations.
Why It Matters: Epithalon’s research profile, notably, includes anti-tumour effects in multiple animal models — an unusual finding for a telomerase activator, and one that researchers propose may be explained by Epithalon’s broader neuroendocrine and immune-regulatory effects counteracting tumour promotion. Understanding this paradox is essential for expert-level evaluation of Epithalon’s risk-benefit research profile.
Epithalon as a Telomerase Activator: The Core Mechanism
The telomerase-activating property of Epithalon was first reported by Khavinson and colleagues (2003) in a study published in Bulletin of Experimental Biology and Medicine. The research demonstrated that Epithalon treatment of human fetal fibroblasts in culture stimulated telomerase activity, increased the number of cells expressing telomerase, and extended the replicative lifespan of the cultured cells beyond the Hayflick limit. This was among the first reports of a peptide compound activating telomerase in human somatic cells.
The molecular mechanism by which Epithalon activates telomerase has been partially characterised. Evidence suggests Epithalon interacts with the promoter region of the TERT gene (telomerase reverse transcriptase — the catalytic component of the telomerase complex) through mechanisms involving chromatin remodelling and transcription factor activity. Studies show Epithalon modulates the activity of c-Myc — a transcription factor known to be a major regulator of TERT promoter activity — and influences histone acetylation patterns in the TERT promoter region, potentially increasing TERT transcription.
Beyond direct telomerase activation, Epithalon has been shown to reduce oxidative DNA damage at telomeric sequences. Telomeres are disproportionately sensitive to oxidative stress due to their guanine-rich sequence (guanine has the lowest oxidation potential of the DNA bases), and oxidative telomere damage accelerates shortening independent of replication. Epithalon’s demonstrated antioxidant effects — through modulation of superoxide dismutase and catalase activity — may protect telomeric sequences from oxidative attrition, providing a second, complementary mechanism for its telomere length-preserving effects.
Pineal Gland, Melatonin, and Neuroendocrine Regulation
Epithalon’s origin from pineal gland-derived peptides is not coincidental to its biological effects — the pineal gland is a central regulator of circadian biology, melatonin synthesis, and neuroendocrine ageing. The progressive calcification and functional atrophy of the pineal gland with age (“pineal aging”) is associated with declining melatonin production, disrupted circadian rhythms, reduced antioxidant capacity, and altered immune function — a cluster of changes that parallel broader biological ageing.
Research demonstrates Epithalon stimulates melatonin synthesis by the pineal gland, both in animal models and in human studies examining plasma melatonin levels in elderly subjects. Since melatonin is a potent antioxidant, immune modulator, and circadian synchroniser, Epithalon’s melatonin-stimulating effects potentially provide a downstream cascade of anti-ageing benefits: improved sleep architecture, enhanced antioxidant protection, normalised cortisol rhythms, and better immune surveillance — effects that connect the telomere-focused mechanism to systemic neuroendocrine benefits.
The neuroendocrine regulatory effects extend beyond melatonin. Khavinson’s research documents Epithalon’s influence on gonadotropin-releasing hormone (GnRH) pulsatility, thyrotropin-releasing hormone (TRH) activity, and adrenocortical function — suggesting the compound acts as a broad neuroendocrine bioregulator that partially reverses the age-related decline in hypothalamic-pituitary axis responsiveness. This positions Epithalon research within the broader field of neuroendocrine theories of ageing, which propose that progressive failure of hypothalamic regulatory circuits is a primary driver of systemic ageing.
Lifespan Extension Studies: Animal Model Evidence
The animal lifespan extension data for Epithalon represents some of the most striking findings in its research portfolio. Multiple rodent studies conducted at Khavinson’s institute have documented statistically significant lifespan extension in Epithalon-treated animals versus vehicle-treated controls, with increases in median lifespan ranging from 13% to 25% depending on the animal model, treatment regimen, and starting age.
A particularly notable study examined the effects of Epithalon administration to aging female C3H/He mice (a strain prone to mammary tumours) beginning at 3 months of age. Treated animals showed a 25% increase in maximum lifespan, reduced tumour incidence compared to controls, and preserved body weight and physical function metrics in late life — suggesting effects on both lifespan and healthspan simultaneously.
Studies in fruit flies (Drosophila melanogaster) also reported lifespan extension with Epithalon treatment — a finding in an evolutionarily distant model organism that supports the conclusion that the mechanism involves conserved ageing pathways rather than rodent-specific biology. The Drosophila data also allowed investigation of genetic mechanisms, with researchers identifying effects on genes in the insulin/IGF-1 signalling and stress response pathways — pathways conserved across essentially all studied model organisms in longevity research.
It bears noting that all animal lifespan studies on Epithalon originate from Khavinson’s institute and have not been independently replicated by other research groups using identical protocols — a significant methodological limitation discussed further in the limitations section.
Key Insight: Khavinson’s animal lifespan studies were conducted under Soviet institutional protocols that differ from modern Western standards in several respects: blinding was not always documented, statistical methods were not always fully specified, and raw data is not publicly available for independent analysis. This does not necessarily mean the findings are incorrect — but it means the evidence certainty level is lower than equivalent modern studies would provide.
Why It Matters: Expert biohackers evaluating Epithalon must calibrate their confidence appropriately. The convergent evidence from multiple study types (cell culture, animal models, human observational studies) increases credibility — but the absence of independent replication and rigorous modern methodology means Epithalon’s lifespan effects should be treated as promising preliminary data rather than established findings.
Human Evidence: Russian Clinical Research
Epithalon’s human evidence base is broader than that of most research peptides — though it requires careful interpretation given the methodological differences between Soviet-era clinical research and modern randomised controlled trial standards. Several clinical studies conducted in Russia from the 1980s through 2000s examined the effects of Epithalamin (the natural pineal extract precursor) and subsequently Epithalon in elderly human subjects.
The most cited human study is a long-term observational investigation of elderly individuals (average age 60–74) who received periodic Epithalamin treatment over a 6–12 year follow-up period, compared to untreated controls. Published reports from this study indicate that treated subjects showed significantly lower all-cause mortality at follow-up than controls — a striking outcome that, if confirmed in rigorous RCTs, would represent one of the most important findings in clinical longevity research. Reported improvements included better preservation of immune function, lower cardiovascular event rates, and reduced cancer incidence.
Additional human studies document Epithalon’s effects on melatonin levels, cortisol rhythms, and various immune parameters in elderly subjects, with results generally consistent with the animal model data showing restoration of younger neuroendocrine profiles. Some studies examined retinal function in ageing subjects, reporting improvements in visual acuity and retinal photoreceptor function with Epithalon treatment — an effect attributed to anti-oxidative protection of the retinal pigment epithelium.
The critical caveat for all of these human studies is that they were not conducted as modern double-blind, randomised, placebo-controlled trials with pre-registered protocols, power calculations, and independent data monitoring. They represent an older tradition of observational and quasi-experimental clinical research whose findings are hypothesis-generating rather than definitive. Independent replication under modern RCT standards would be required to confirm any of these findings clinically.
Cancer Biology and Anti-Tumour Research
One of the most scientifically intriguing aspects of Epithalon’s research profile is its apparent anti-tumour activity in preclinical models — a paradoxical finding for a telomerase activator, given that most cancers depend on telomerase for their replicative immortality. Multiple animal studies have documented reduced spontaneous tumour incidence and, in some models, reduced tumour growth rates in Epithalon-treated animals versus controls.
The proposed explanation for this apparent paradox involves Epithalon’s immune-stimulating and antioxidant effects operating in parallel with its telomerase activation. In the context of normal somatic cells with regulated cell cycle checkpoints, telomerase activation may extend replicative lifespan without enabling uncontrolled proliferation. In tumour cells that have already undergone multiple oncogenic mutations disrupting cell cycle regulation, Epithalon’s immune-enhancement may simultaneously improve anti-tumour surveillance, potentially offsetting any pro-survival benefit tumour cells might receive from telomerase stimulation.
This area of research is at an early stage and the mechanistic explanations remain speculative. Expert researchers should approach the anti-tumour claims with the same calibrated caution as the lifespan extension data — the findings are interesting and the mechanisms proposed are biologically plausible, but independent replication and more rigorous mechanistic studies are needed before strong conclusions can be drawn.
Gene Expression and Epigenetic Research
Recent genomic research has begun to characterise Epithalon’s effects at the level of gene expression and epigenetic regulation — an approach that connects Epithalon research to the broader field of epigenetic ageing and the “epigenetic clock” models developed by researchers such as Steve Horvath. Studies by Khavinson’s group have documented that Epithalon modulates the expression of genes involved in antioxidant defence, inflammatory regulation, cell cycle control, and DNA repair.
Particularly relevant is research showing Epithalon affects the expression of genes regulated by PCNA (Proliferating Cell Nuclear Antigen), a key coordinator of DNA replication and repair. Normalisation of PCNA-dependent gene expression in aged cells may partially restore the more efficient DNA repair capacity of younger cells — a mechanistic link between Epithalon treatment and reduced oxidative DNA damage observed in treated animals.
The epigenetic clock hypothesis — that biological age can be measured more accurately by DNA methylation patterns than by chronological age — provides a potential framework for future Epithalon research. If Epithalon’s gene expression effects extend to methylation pattern changes associated with biological rejuvenation, it would represent convergent evidence with the lifespan and telomere data. This remains an active research question as of 2025.
Epithalon vs Other Longevity Peptides: Research Comparison
| Feature | Epithalon | MOTS-C | GHK-Cu |
|---|---|---|---|
| Primary Mechanism | Telomerase activation, melatonin synthesis, TERT promoter modulation | AMPK activation, mitochondrial retrograde signalling, NRF2 | Collagen synthesis, VEGF signalling, ~4,000 gene modulation |
| Genetic Origin | Derived from bovine pineal peptides; synthetically reproduced | Mitochondrial DNA-encoded (12S rRNA gene) | Endogenous human plasma peptide |
| Lifespan Animal Data | 13–25% increase in rodents (Khavinson group) | Significant extension in aged female mice (Kim et al., 2021) | Not directly studied for lifespan extension |
| Human Evidence | Soviet-era clinical studies; mortality reduction data (methodologically limited) | Cross-sectional biomarker studies; centenarian genetics | Small human dermatology trials |
| Research Group Diversity | Primarily Khavinson institute; limited independent replication | USC, Buck Institute, multiple global groups | Multiple independent groups globally |
| Exercise Connection | No direct exercise-related mechanism | Exercise mimetic — AMPK-mediated | Minimal direct exercise connection |
Key Research Numbers
Statistics Section: Epithalon in Numbers
- 4 amino acids — Length of Epithalon (Ala-Glu-Asp-Gly); one of the smallest biologically active peptides studied in longevity research
- ~390 Da — Molecular weight of Epithalon
- 40+ years — Duration of Epithalon/Epithalamin research at Khavinson’s institute since the 1970s
- 13–25% — Range of median lifespan increase reported in Epithalon-treated rodent studies
- 2003 — Year of first published report of Epithalon activating telomerase in human fetal fibroblasts
- 85–90% — Percentage of human cancers that are telomerase-positive (contextualising the telomerase paradox)
- 50–70 — Hayflick limit: approximate maximum cell divisions for human somatic cells before telomere-induced senescence
- TTAGGG — Telomere repeat sequence in vertebrates that Epithalon’s telomerase activation maintains
The Biohacker Perspective: Epithalon in Self-Experimentation Culture
Epithalon has a well-established presence in biohacker and longevity self-experimentation communities — a cultural phenomenon that expert researchers should understand both to engage productively with biohacker audiences and to critically evaluate the anecdotal reports that circulate in these communities. The compound’s appeal to biohackers is straightforward: it is one of very few peptides with both a mechanistic connection to telomere biology (a central interest of the anti-ageing biohacker community) and some form of human data suggesting longevity-associated benefit.
Biohacker communities — particularly groups organised around the work of researchers like Aubrey de Grey, David Sinclair, and Peter Attia — are deeply interested in telomere length as a biomarker of biological age, and many practitioners self-administer Epithalon cyclically (typically described as a “course” of daily doses over 10–20 days, repeated one to several times per year) while tracking telomere length via commercial telomere testing services as a personal outcome measure.
From a scientific standpoint, the self-experimentation data generated by biohacker communities is not controlled, not blinded, and subject to reporting bias — most published personal accounts document positive outcomes, and the selection pressures in online communities create a biased sample of reported experiences. However, the scale of self-experimentation occurring globally does represent an informal pharmacovigilance system that has not, as of 2025, generated notable signals of serious adverse events — a weak but not entirely uninformative safety datapoint.
Expert researchers engaging with biohacker audiences on Epithalon should acknowledge the legitimate scientific interest in its telomere and longevity mechanisms while being precise about the distinction between preliminary research evidence and established clinical outcomes. The credibility gap between the scientific community and biohacker communities on research peptides is often widened unnecessarily by dismissal of the underlying science — Epithalon’s mechanisms are genuinely interesting and the evidence base, while imperfect, is more substantial than for many other self-experimented compounds.
Limitations and Research Gaps
The Epithalon evidence base carries significant limitations that distinguish it from compounds studied by multiple independent global research groups under modern methodological standards. The most fundamental concern is research concentration: virtually all meaningful Epithalon studies originate from Khavinson’s Institute of Bioregulation and Gerontology. While Khavinson is a legitimate and prolific scientist with an extensive publication record, the absence of independent replication means that potential investigator bias, institutional publication bias, or systematic methodological idiosyncrasies could affect the published record without detection.
The human clinical data, while more extensive than most research peptides, does not meet modern RCT standards. The lack of pre-registration, blinding, standardised outcome measures, and publicly available raw data makes these studies difficult to evaluate or integrate with Western clinical evidence standards. They are best classified as hypothesis-generating observational research rather than confirmatory evidence.
Human pharmacokinetic data is largely absent. How Epithalon is absorbed, distributed, metabolised, and eliminated in humans — and what plasma concentrations are achieved at various doses — has not been systematically characterised in published form. This makes rational dose selection for research purposes challenging.
The telomerase paradox remains unresolved in Epithalon-specific research: the mechanisms by which a telomerase activator simultaneously reduces tumour incidence in animal models have not been mechanistically dissected in rigorous independent studies. Until this paradox is resolved, the oncological safety profile of chronic Epithalon administration in humans with unknown subclinical tumour burden remains a relevant research question.
Frequently Asked Questions
A: Epithalamin is the natural polypeptide extract from bovine pineal glands, containing a complex mixture of peptides and other biological molecules. Epithalon (Ala-Glu-Asp-Gly) is the synthetically produced tetrapeptide identified as the minimal active sequence within Epithalamin responsible for its core biological effects. Epithalon offers the advantages of defined composition, precise purity, and reproducible manufacturing compared to the variable natural extract.
A: Research indicates Epithalon modulates the TERT gene promoter through mechanisms involving changes in chromatin structure (histone acetylation patterns) and transcription factor activity — including c-Myc, a known TERT transcriptional activator. Additionally, Epithalon’s antioxidant effects may reduce oxidative damage to telomeric DNA, providing a second mechanism for preserving telomere length independent of direct telomerase activation.
A: This apparent paradox is one of the most discussed aspects of Epithalon research. The proposed explanation involves Epithalon’s parallel immune-enhancing and antioxidant effects potentially improving anti-tumour immune surveillance and reducing oncogenic oxidative DNA damage — effects that may outweigh any pro-survival benefit tumour cells receive from telomerase stimulation. This remains an area requiring more mechanistic investigation.
A: Human evidence comes primarily from Soviet-era clinical studies by Khavinson’s group, including observational data on elderly subjects showing reduced all-cause mortality, improved immune parameters, and better neuroendocrine profiles in Epithalamin/Epithalon-treated groups versus untreated controls. These studies do not meet modern RCT standards (lack of double-blinding, pre-registration, power calculations), making them hypothesis-generating rather than confirmatory. Independent Western clinical trials have not been conducted.
A: Research demonstrates Epithalon stimulates melatonin synthesis by the pineal gland in both animal models and human subjects. Since melatonin declines with age as the pineal gland atrophies, Epithalon’s melatonin-stimulating effects may contribute to downstream benefits including improved sleep quality, enhanced antioxidant capacity (melatonin is a potent free radical scavenger), normalised circadian rhythms, and improved immune function — all of which are associated with healthy ageing.
A: Epithalon’s published safety profile in preclinical studies is generally favourable — no significant toxicity has been reported in animal studies across the doses examined. The Soviet-era human studies also do not report significant adverse events. However, long-term human pharmacokinetic and safety data from rigorous controlled studies are absent, and the theoretical oncological concern around chronic telomerase activation in individuals with undetected subclinical tumours remains an important consideration for any human research involving Epithalon.
A: Published animal studies have used various administration regimens. Human studies from Khavinson’s group used cyclical treatment courses of Epithalamin/Epithalon administered over 10 days, repeated periodically (typically 1–2 courses per year). These protocols are not standardised or validated for human research purposes and should not be interpreted as dosing recommendations. Any human research involving Epithalon must be conducted under appropriate institutional oversight and ethical approval.
A: Vietnam Peptides supplies research-grade Epithalon 10mg for scientific investigators studying telomere biology, neuroendocrine ageing, and longevity-associated pathways. Products are supplied strictly for scientific research. Researchers should verify applicable local regulations before procurement.
Related Articles
- Vietnam Peptides Knowledge Hub — expert guides on longevity peptides, telomere biology, and anti-ageing research
- Peptide FAQ: Research, Storage and Usage
- Browse Longevity Research Peptides
Related Research Products
Research-grade synthetic tetrapeptide for telomere biology, telomerase activation, and neuroendocrine longevity research.
View Product →Mitochondria-derived longevity peptide for AMPK activation, metabolic health, and complementary longevity pathway research.
View Product →Related Research Plans
For biohackers and longevity researchers investigating telomere biology, epigenetic ageing, and neuroendocrine optimisation, the Vietnam Peptides Longevity Plan provides a structured compound selection framework aligned with current geroscience evidence.
Explore the Longevity Plan →Scientific References
- Khavinson VKh, Bondarev IE, Butyugov AA. (2003). Epithalon peptide induces telomerase activity and telomere elongation in human somatic cells. Bull Exp Biol Med. 135(6):590–2. DOI: 10.1023/a:1025493705728
- Anisimov VN, Khavinson VKh, Provinciali M, et al. (2006). Inhibitory effect of the peptide epitalon on the development of spontaneous mammary tumors in HER-2/neu transgenic mice. Int J Cancer. 101(1):7–10. DOI: 10.1002/ijc.10570
- Khavinson V, Diomede F, Mironova E, et al. (2020). AEDG Peptide (Epitalon) Stimulates Gene Expression and Protein Synthesis during Neurogenesis: Possible Epigenetic Mechanism. Molecules. 25(3):609. DOI: 10.3390/molecules25030609
- Anisimov VN, Khavinson VKh, Alimova IN, et al. (2003). Epithalon decelerates aging and suppresses development of breast adenocarcinomas in transgenic her-2/neu mice. Bull Exp Biol Med. 135(6):532–5. DOI: 10.1023/a:1025404616359
- Khavinson VKh, Bondarev IE, Butyugov AA, Smirnova TD. (2004). Peptide promotes overcoming of the division limit in human somatic cells. Bull Exp Biol Med. 137(5):503–6. DOI: 10.1023/b:bebm.0000038164.49947.8c
- Blackburn EH, Epel ES, Lin J. (2015). Human telomere biology: A contributory and interactive factor in aging, disease risks, and protection. Science. 350(6265):1193–8. DOI: 10.1126/science.aab3389
- Greider CW, Blackburn EH. (1985). Identification of a specific telomere terminal transferase activity in Tetrahymena extracts. Cell. 43(2 Pt 1):405–13. DOI: 10.1016/0092-8674(85)90170-9
- Shay JW, Wright WE. (2019). Telomeres and telomerase: three decades of progress. Nat Rev Genet. 20(5):299–309. DOI: 10.1038/s41576-019-0099-1
Conclusion
Epithalon occupies a unique position in the longevity peptide research landscape: it is the only peptide compound with published evidence of telomerase activation in human cells, supported by over 40 years of preclinical and some human research documenting anti-ageing, lifespan-extending, neuroendocrine-regulatory, and anti-tumour effects. For expert biohackers and longevity researchers, these properties make it a compound of serious scientific interest.
The limitations of the evidence base — primarily the concentration of research within Khavinson’s institute and the methodological gaps in Soviet-era clinical studies — require expert researchers to maintain appropriate epistemic caution while acknowledging the genuine biological plausibility and substantial preclinical support for Epithalon’s longevity-related mechanisms. The telomerase paradox, while unresolved, does not undermine the compound’s research interest — it adds a dimension of mechanistic complexity that warrants investigation rather than dismissal.
Vietnam Peptides supplies research-grade Epithalon 10mg for scientific investigators. Explore the full product range at the Products Page and visit the Knowledge Hub for additional longevity research resources.
Primary Entity: Epithalon (Epitalon) Tetrapeptide — Ala-Glu-Asp-Gly
Related Entities: Vladimir Khavinson, Epithalamin, Pineal Gland, Telomerase, TERT Gene, Telomere Length, Hayflick Limit, Melatonin, c-Myc Transcription Factor, DNA Methylation, Epigenetic Clock, MOTS-C, GHK-Cu, St. Petersburg Institute of Bioregulation and Gerontology
Search Intent: Informational / Research-Oriented — expert understanding of Epithalon, telomere activation mechanism, longevity evidence
Key Questions Answered: What is Epithalon? How does Epithalon activate telomerase? Epithalon vs Epithalamin? Does Epithalon extend lifespan? Human evidence for Epithalon? Epithalon and cancer safety? How does Epithalon affect melatonin?
Evidence Sources: Khavinson et al. 2003 (Bull Exp Biol Med), Anisimov et al. 2006 (Int J Cancer), Khavinson et al. 2020 (Molecules), Blackburn et al. 2015 (Science), Shay & Wright 2019 (Nat Rev Genet)
Relevant User Profiles: Biohackers, Longevity Enthusiasts, Geroscience Researchers, Functional Medicine Practitioners, Anti-Aging Research Scientists
Knowledge Graph Connections: Epithalon → Telomerase Activation → TERT Gene → Telomere Length → Cellular Senescence → Longevity → Pineal Gland → Melatonin → Neuroendocrine Ageing → Anti-Cancer Research → Biohacker Community